2.71
+0.05(+1.88%)
Currency In USD
| Previous Close | 2.66 |
| Open | 2.66 |
| Day High | 2.74 |
| Day Low | 2.59 |
| 52-Week High | 3.48 |
| 52-Week Low | 1.05 |
| Volume | 561,835 |
| Average Volume | 1.32M |
| Market Cap | 293.62M |
| PE | -1.72 |
| EPS | -1.58 |
| Moving Average 50 Days | 2.76 |
| Moving Average 200 Days | 1.9 |
| Change | 0.05 |
If you invested $1000 in Aclaris Therapeutics, Inc. (ACRS) 10 years ago, it would be worth $128.13 as of January 14, 2026 at a share price of $2.71. Whereas If you bought $1000 worth of Aclaris Therapeutics, Inc. (ACRS) shares 5 years ago, it would be worth $444.26 as of January 14, 2026 at a share price of $2.71.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052
GlobeNewswire Inc.
Jan 12, 2026 11:55 AM GMT
WAYNE, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiat
Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development
GlobeNewswire Inc.
Jan 06, 2026 11:59 AM GMT
- Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial Reinforce Potential Best-in-Class Potency Advantage of ATI-052 - - Trial Results Support Potential for Extended Dosing of up to Every Three Months - - Initiat
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)
GlobeNewswire Inc.
Dec 19, 2025 9:01 PM GMT
WAYNE, Pa., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced it has been added t